226 related articles for article (PubMed ID: 25043543)
1. [Achievement of therapeutic objectives].
Mantilla T
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():20-4. PubMed ID: 25043543
[TBL] [Abstract][Full Text] [Related]
2. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy studies].
Pedro-Botet J; Flores-Le Roux JA
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
[TBL] [Abstract][Full Text] [Related]
4. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
[TBL] [Abstract][Full Text] [Related]
5. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Hernández Mijares A
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
[TBL] [Abstract][Full Text] [Related]
6. [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
Pintó X
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():35-9. PubMed ID: 25043546
[TBL] [Abstract][Full Text] [Related]
7. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Pérez A
Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
[No Abstract] [Full Text] [Related]
8. [Treatment of older patients with dyslipidemia].
González DF
Semergen; 2014 May; 40 Suppl 1():17-21. PubMed ID: 25263639
[TBL] [Abstract][Full Text] [Related]
9. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
10. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
[TBL] [Abstract][Full Text] [Related]
11. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
12. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
González Santos P
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
Filippatos TD; Elisaf MS
Expert Opin Pharmacother; 2011 Aug; 12(12):1945-58. PubMed ID: 21736529
[TBL] [Abstract][Full Text] [Related]
15. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
Farnier M
Expert Rev Cardiovasc Ther; 2012 May; 10(5):565-75. PubMed ID: 22651832
[TBL] [Abstract][Full Text] [Related]
16. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
Olsson AG
Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
[No Abstract] [Full Text] [Related]
17. [Reasons for a combination].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547
[No Abstract] [Full Text] [Related]
18. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
[TBL] [Abstract][Full Text] [Related]
19. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
20. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
Farnier M; Marcereuil D; De Niet S; Ducobu J; Steinmetz A; Retterstøl K; Bryniarski L; Császár A; Vanderbist F
Clin Drug Investig; 2012 Apr; 32(4):281-91. PubMed ID: 22350498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
